Cyclacel Pharmaceuticals Q2 2024 GAAP EPS $(0.72) Beats $(1.44) Estimate, Sales $4.00K Miss $30.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported a Q2 2024 GAAP EPS of $(0.72), beating the analyst estimate of $(1.44). However, sales were $4.00K, missing the $30.00K estimate and showing a 98.93% decrease from the same period last year.
August 14, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cyclacel Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.72), beating the analyst estimate of $(1.44). However, sales were $4.00K, missing the $30.00K estimate and showing a 98.93% decrease from the same period last year.
While Cyclacel Pharmaceuticals beat the EPS estimate significantly, the substantial miss on sales and the drastic year-over-year decline in revenue could neutralize the positive impact of the EPS beat. Investors may have mixed reactions, leading to a neutral short-term price impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100